Waters' Q4 Revenues Flat; High-end Mass Spec Business Improving | GenomeWeb

NEW YORK (GenomeWeb News) – Waters today said that fourth-quarter revenues were essentially flat year over year as the firm missed analyst estimates on the top line but beat it on the bottom line.

For the three months ended Dec. 31, 2012 Waters posted $521.8 million in revenues compared to $521.4 million a year ago, missing the consensus Wall Street estimate of $522.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.